The prostate will be the site for the diagnosis of cancer in more men in the United States than any other organ. Owing to the staggering incidence, coupled with the lack of uniformity in opinion as to the optimum therapy, men are overwhelmed with various differing therapeutic options. The lay press, self-help books and most importantly the World Wide Web inundate patients with information, a great deal of which has little merit, much less peer reviewed. All of us who treat men with this disease frequently see patients in our consulting rooms with literally hundreds and hundreds of pages of material that they have studied searching for an answer.
Part of the problem in prostate cancer stems from the fact that the two major forms of therapy for cure: radiation therapy (brachytherapy or external beam); and radical prostatectomy, are championed by two different disciplines: radiation oncologists and urologists. The discipline of the physician counseling the patient has a major impact on the recommendation for therapy. For example, Fowler and associates 1 surveyed a random sample of urologists and radiation oncologists throughout the United States and not surprisingly, 93% of the urologists chose radical prostatectomy as the preferred treatment option for men with moderately differentiated clinically localized cancer with more than a 10-y life expectancy. In contrast, 72% of radiation oncologists felt that surgery and external beam radiation therapy provided equivalent treatments. For most groupings of Gleason score and PSA levels, radiation oncologists recommended radiation and urologists recommended radical prostatectomy.
The specialty bias may not always be appreciated by the patient. The optimum therapeutic regimen for clinically localized prostate cancer remains obscure. This can only be determined by prospective randomized comparative trials. The American Urological Association as well as the American College of Physicians guideline panels have concluded that we are in a state of equipose such that radical prostatectomy and radiation therapy and indeed surveillance are all acceptable options. This is because comparative studies demonstrating clear-cut advantage of one form of therapy over another have not been reported. 23 Some important trials are currently in place. For example, the Prostate cancer Intervention vs Observation Trial (PIVOT) is actively recruiting men with clinically localized disease to be randomized to radical prostatectomy vs watchful waiting. Although accrual has been slower than planned, approximately 700 men have been randomized. Because all cause survival is the major endpoint of this trial, it is anticipated that a de®nitive answer, with results, will require many more years. Because of the complexity of health care delivery in the United States, it is unclear whether the trial randomizing men to radical prostatectomy vs radiation therapy currently being initiated will be successfully completed.
While we can encourage participation in randomized trials, we know that the majority of men will not avail themselves of these. Thus we are left with the quandary: how is the patient most appropriately, and without bias, counseled?
Some have suggested 4 that the primary care practitioner plays a key role in guiding the patient into a path of treatment. In the best possible scenario this is an ideal solution, given the fact that an intrinsic bias (in part no doubt economic) would be obviated by an interested but not con¯icted third party practitioner who would have the patient's well being as his or her only motivation. This approach, however, has signi®cant problems. Most fundamentally, practitioners neither have the time in their practice nor the knowledge about the nuances of prostate cancer and treatment options to serve as an`expert' in helping the patient's deliberation.
I believe that the only rational approach to guiding our patients is by having skilled clinicians with signi®cant experience in treating prostate cancer provide the counseling. I believe that the patient is best served when urologists who perform both radical prostatectomies and brachytherapy provide the initial counseling experience. For patients thinking about radiation therapy by external beam, obviously radiation oncologists would be the more important counseling individuals. At the Northwest Prostate Institute, brachytherapy has always been performed with a team approach utilizing radiation oncologists and urologists. The urologist who performs both approaches can more de®nitively explain the risks and bene®ts of radical prostatectomy and brachytherapy.
An important issue is the lack of ef®cacy and comparative morbidity studies. Without a randomized trial it is unlikely that a de®nitive statement in this regard will ever be forthcoming. Although the brachytherapy series are now more mature, 5 they will always lag behind long term follow-up with the radical prostatectomy series.
After spending at least an hour with a patient with newly diagnosed prostate cancer I generally conclude my counseling with the statement that it is my belief that radical prostatectomy may provide a slightly greater chance of cure compared to brachytherapy but with more morbidity. Patients seem able to integrate this objective but simple differentiation into their and their partners expectations and personal goals with greater clarity than can be afforded by the information overload which they so often bring into my of®ce. I believe that the patient is best served by being counseled by a physician who can provide detailed information based in part on his or her own experience of performing both brachytherapy and radical prostatectomy. Failing this, a close relationship between urologists and radiation oncologists, ideally in a multi-disciplinary clinic, may serve as a close second. Eventually perhaps we will have a de®ni-tive answer based on clinical trials. Unfortunately, comparing contemporary patients to those we treat in the future will be problematic, given the inevitable changes in diagnosis, staging and therapeutic approaches to this most common of all human neoplasms.
